![Ralf Morgenstern](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ralf Morgenstern
Corporate Officer/Principal chez Karolinska Institutet
Postes actifs de Ralf Morgenstern
Sociétés | Poste | Début | Fin |
---|---|---|---|
Karolinska Institutet | Corporate Officer/Principal | 06/05/2010 | - |
Historique de carrière de Ralf Morgenstern
Anciens postes connus de Ralf Morgenstern
Sociétés | Poste | Début | Fin |
---|---|---|---|
NovaSAID AB
![]() NovaSAID AB Pharmaceuticals: MajorHealth Technology NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden. | Directeur/Membre du Conseil | 26/10/2004 | - |
Fondateur | 26/10/2004 | - |
Statistiques
Internationale
Suède | 3 |
Opérationnelle
Corporate Officer/Principal | 1 |
Director/Board Member | 1 |
Founder | 1 |
Sectorielle
Consumer Services | 2 |
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
NovaSAID AB
![]() NovaSAID AB Pharmaceuticals: MajorHealth Technology NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden. | Health Technology |
- Bourse
- Insiders
- Ralf Morgenstern
- Expérience